Uncommon EGFR mutations in advanced non-small cell lung cancer

Grainne M. O'Kane, Penelope A. Bradbury, Ronald Feld, Natasha B. Leighl, Geoffrey Liu, Katherine M. Pisters, Suzanne Kamel-Reid, Ming S. Tsao, Frances A. Shepherd

Research output: Contribution to journalReview articlepeer-review

133 Scopus citations

Abstract

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the detection of actionable mutations, which has revolutionized the treatment paradigm in this highly fatal disease. Mutations involving the epidermal growth factor receptor (EGFR) gene are most common and the ‘classical mutations’, exon 19 deletions and the point mutation L858R at exon 21, predict response to EGFR tyrosine kinase inhibitors (TKIs). The ‘uncommon’ EGFR mutations account for 10–18% of all EGFR mutations and primarily consist of exon 20 insertions, exon 18 point mutations and complex mutations. Improved detection techniques have broadened the spectrum of reported aberrations within the ‘uncommon group’ but response to TKIs is variable and not fully elucidated. This review provides an overview of the biology and incidence of uncommon EGFR mutations and summarizes reported outcomes when treated with EGFR-TKIs.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalLung Cancer
Volume109
DOIs
StatePublished - Jul 2017
Externally publishedYes

Keywords

  • EGFR mutations
  • NSCLC
  • Tyrosine kinase inhibitors
  • Uncommon

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Uncommon EGFR mutations in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this